Lamivudine therapy of chronic hepatitis B in three groups of patients: Non transplanted patients, liver recipients, and kidney recipients

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 1, 2002, Pages 62-66

  Schvoerer, Evelyne ^a,d   Kabissa, Imed ^b   Cotto, Emmanuelle ^a   Jouvencel, Anne Christine ^a   Balabaud, Charles ^b   De Ledinghen, Victor ^b   Couzigou, Patrice ^b   Quinton, André ^b   Schvoerer, Claire ^c   Lafon, Marie Edith ^a   Fleury, Hervé ^a   Bernard, Pierre Henri ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c Direction Régionale des Affaires Sanitaires et Sociales de Bretagne ^*  (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LIVER ENZYME; VIRUS DNA;

ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA PROBE; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; NUCLEOTIDE SEQUENCE; SEROLOGY;

ALANINE TRANSAMINASE; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; FEMALE; GENE PRODUCTS, POL; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MUTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036188658     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan
2. The treatment of chronic viral hepatitis
3. Long-term follow-up of HBeAg positive patients with chronic active hepatitis after ct-interferon therapy
4. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
5. A one-year trial of lamivudine for chronic hepatitis B
6. Hepatitis B reactivation after lamivudine
7. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
8. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
9. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
10. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
11. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
12. Classification of chronic hepatitis: Diagnosis, grading and staging
13. Long-term therapy of chronic hepatitis B with lamivudine
14. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
15. Lamivudine resistance in hepatitis B: Mechanisms and clinical implications
16. Lamivudine at initial treatment for chronic hepatitis B in the United States
17. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
18. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
19. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
20. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
21. Lamivudine treatment for acute hepatitis B after liver transplantation
22. Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children
23. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation
24. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis
25. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation
26. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus
27. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
28. Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant
29. Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation
30. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy
31. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients
32. Results on preemptive or prophylactic treatment in HbsAg (+) renal allograft recipients: Comparison with salvage treatment after hepatic dysfunction with HBV recurrence
33. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
34. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis